Literature DB >> 20032327

Lp(a) lipoprotein redux--from curious molecule to causal risk factor.

Sekar Kathiresan.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 20032327     DOI： 10.1056/NEJMe0910792

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

Review 1.  Lipoprotein (a): Coming of Age at Last.

Authors:  Joseph L Witztum; Henry N Ginsberg
Journal:  J Lipid Res       Date:  2016-02-02       Impact factor: 5.922

2.  Dyslipidaemia: PCSK9 antibodies: a dividend of the genomics revolution.

Authors:  Michael H Davidson
Journal:  Nat Rev Cardiol       Date:  2013-09-10       Impact factor: 32.419

Review 3.  Targeting lipoprotein (a): an evolving therapeutic landscape.

Authors:  Lillian C Man; Erik Kelly; Danielle Duffy
Journal:  Curr Atheroscler Rep       Date:  2015-05       Impact factor: 5.113

4.  Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia.

Authors:  Adie Viljoen; Anthony S Wierzbicki
Journal:  Drug Healthc Patient Saf       Date:  2010-05-24

Review 5.  The Potential Role of Genomic Medicine in the Therapeutic Management of Rheumatoid Arthritis.

Authors:  Marialbert Acosta-Herrera; David González-Serna; Javier Martín
Journal:  J Clin Med       Date:  2019-06-10       Impact factor: 4.241
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.